Clinical predictor | OR (95% CI) | p Value |
---|---|---|
Age (per year increase) | 1.01 (0.95 to 1.05) | 0.80 |
Male (vs. female) | 1.20 (0.44 to 3.24) | 0.72 |
Homozygous F508del (vs non-homozygous F508del) | 1.24 (0.47 to 3.29) | 0.67 |
BMI (per kg/m2 increase) | 0.87 (0.75 to 1.02) | 0.08 |
FEV1 (per % predicted increase) | 0.99 (0.97 to 1.00) | 0.13 |
Sputum microbiology | ||
MSSA | 0.79 (0.31 to 2.04) | 0.63 |
MRSA | 0.63 (0.14 to 2.75) | 0.54 |
Pseudomonas aeruginosa | 2.79 (1.05 to 7.40) | 0.04 |
Stenotrophomonas maltophilia | 1.34 (0.08 to 22.4) | 0.84 |
Burkholderia cepacia complex | 0.40 (0.08 to 2.16) | 0.29 |
CF-related diabetes | 1.29 (0.35 to 4.75) | 0.70 |
Exacerbation requiring intravenous antibiotics in prior year | 2.29 (0.83 to 6.34) | 0.11 |
Current therapies | ||
Inhaled antibiotics | 1.25 (0.42 to 3.75) | 0.69 |
Oral azithromycin | 1.24 (0.47 to 3.29) | 0.67 |
BMI, body mass index; MRSA, methicillin-resistant Staphylococcus aureus; MSSA, methicillin-sensitive S. aureus.